The Filing Desk

Kiniksa Pharmaceuticals vs Ultragenyx Pharmaceutical

Kiniksa Pharmaceuticals KNSA · Ultragenyx Pharmaceutical RARE · Pharmaceuticals

Kiniksa Pharmaceuticals reported revenue of $678 million in fiscal 2025, about the same as Ultragenyx Pharmaceutical's $673 million in fiscal 2025. Kiniksa Pharmaceuticals' revenue grew 60.1% in its latest year, and Ultragenyx Pharmaceutical's grew 20.2%. Kiniksa Pharmaceuticals had an operating margin of 11.4%, against -79.5% at Ultragenyx Pharmaceutical. Free cash flow was $136 million at Kiniksa Pharmaceuticals and −$472 million at Ultragenyx Pharmaceutical.

Side by side

Kiniksa PharmaceuticalsUltragenyx Pharmaceutical
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$678M$673M
Revenue growth60.1%20.2%
Revenue growth a year, last 5 years—20.0%
Gross margin88.5%—
Operating margin11.4%−79.5%
Net margin8.7%−85.4%
Free cash flow$136M−$472M
Free cash flow margin20.1%−70.1%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count10.6%8.9%
Last close$96.33$16.08
P/E at the last close73.5×—
Insider trades, last 12 monthssold $45.1 millionsold $3.7 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Kiniksa PharmaceuticalsUltragenyx Pharmaceutical
Operating margin
Percent of revenue
Kiniksa PharmaceuticalsUltragenyx Pharmaceutical
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Kiniksa PharmaceuticalsUltragenyx Pharmaceutical

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Kiniksa Pharmaceuticals and Ultragenyx Pharmaceutical pages.